Roche's Tecentriq cocktail adds to lung cancer survival success
ZURICH (Reuters) - Roche's Tecentriq immunotherapy combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Health | Immunotherapy | Lung Cancer | Merck | Switzerland Health